| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0090-4295(00)00664-6 |
| P698 | PubMed publication ID | 10925083 |
| P50 | author | Michele Lodde | Q40513918 |
| P2093 | author name string | A Haitel | |
| A Pycha | |||
| M Marberger | |||
| C Mian | |||
| E Egarter Vigl | |||
| P2860 | cites work | Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer | Q44338858 |
| Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer | Q48013582 | ||
| Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer | Q73168323 | ||
| Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer | Q73200357 | ||
| Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder | Q73477491 | ||
| Improved detection of recurrent bladder cancer using the Bard BTA stat Test | Q73707842 | ||
| Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? | Q74581865 | ||
| Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract | Q77346911 | ||
| Noninvasive detection of bladder cancer with the BTA stat test | Q77895646 | ||
| Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat | Q77914296 | ||
| Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer | Q77954574 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 228-231 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder | |
| P478 | volume | 56 |
| Q38921522 | A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer |
| Q37277962 | A list of candidate cancer biomarkers for targeted proteomics |
| Q35876409 | Alternatives to cytology in the management of non-muscle invasive bladder cancer |
| Q26775990 | Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise |
| Q36363221 | Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers |
| Q74455549 | Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests |
| Q33915293 | Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? |
| Q24654929 | Critical evaluation of urinary markers for bladder cancer detection and monitoring |
| Q35192390 | Current bladder cancer tests: unnecessary or beneficial? |
| Q37507532 | Diagnosis of urothelial carcinoma from urine |
| Q54449190 | Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. |
| Q80608577 | ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma |
| Q36526271 | Molecular markers in bladder cancer: a critical appraisal |
| Q57825491 | Qualitative and Quantitative Detection of Urinary Human Complement Factor H-Related Protein (BTA stat and BTA TRAK) and Fragments of Cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as Markers for Transitional Cell Carcinoma of the Bladder |
| Q57909053 | The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine |
| Q41455261 | Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study. |
| Q38122367 | Urinary markers for bladder cancer |
| Q38094284 | Urinary markers/cytology: what and when should a urologist use. |
| Q38967481 | Urothelial Bladder Cancer Urinary Biomarkers |
Search more.